Table 1.
Ref.
|
Journal
|
No. of patients
|
Biomarker
|
Method
|
Main findings
|
Ankeny et al[76], 2016 | Br J Cancer | 72 | CTC | Microfluidic NanoVelcro CTC chip | Detection rate of PDAC: 54/72 (sensitivity = 75.0%, specificity = 96.4%) |
Rhim et al[77], 2014 | Gastroenterology | 51 | CTC | Microfluidic geometrically enhanced differential immunocapture | CTC (≥ 3) in 33% of patients with cystic lesions and no clinical diagnosis of cancer, 73% with PDAC, and 0% of controls |
Xu et al[78], 2017 | Int J Mol Sci | 40 | CTC | NE-iFISH | The positive rate of diagnosis of PDAC is nearly 97% in combination with CA19-9 |
Poruk et al[79], 2017 | Clin Cancer Res | 60 | CTC | ISET method & immunofluorescence | The positive rate is 12% in stageⅠPDAC |
Gao et al[80], 2016 | J Exp Clin Cancer Res | 25 | CTC | SE-iFISH platform | Sensitivity of 88 % and specificity of 90 % in PDAC |
Kulemann et al[81], 2015 | Pancreas | 11 | CTC | ScreenCell; Cyto kit | No difference in the rate of CTC detection between early-stage and advanced-stage diseases (P = 0.71) |
Melo et al[33], 2015 | Nature | 56 | Exosome | FACS analysis | The sensitivity and specificity of GPC1+ circulating exosomes in diagnosing PDAC were both 100% |
Buscail et al[82], 2019 | Cancers | 30 | Exosome and CTC | FACS, Cellsearch and RosetteSepTM | Combining quantification of GPC1-positive exosomes and CTC detection identified all the PDAC patients, showed a negative predictive value of 100%, and an overall diagnostic accuracy of 91% |
Lai et al[83], 2017 | Cancer Lett | 40 | Exosome and miRNA | LC-MS & RT-qPCR | High levels of exosomal miR-10b, miR-21, miR-30c, and miR-181a and low levels of miR-let7a differentiated PDAC from healthy and chronic pancreatitis samples |
Liang et al[84], 2017 | Nat Biomed Eng | 23 | EV | nPES assay | Pre-therapy EphA2-EV blood levels accurately distinguished stage I/II pancreatic cancer patients from NC (AUC = 0.96) and pancreatitis patients (AUC = 0.93) |
Que et al[85], 2013 | World J Surg Oncol | 49 | miRNA | RT-PCR | Serum exosomal miR-17-5p was higher in PDAC patients than in non–PDAC patients and healthy participants |
Cote et al[86], 2014 | Am J Gastroenterol | 215 | miRNA | RT-PCR | Increased expression of miRNA-10b, -155, and -106b in plasma appears highly accurate in diagnosing PDAC |
Ouyang et al[87], 2015 | Oncogene | 42 | miRNA | RT-PCR | Plasma miR-10b levels significantly increased in comparison with normal controls |
Slater et al[88], 2014 | Transl Oncol | 59 | miRNA | Real-time PCR | A combination test of miRNA-196a and miRNA-196b, whose expression is upregulated from the PanIN state, can identify patients with PanIN 2/3 |
Madhavan et al[89], 2015 | Int J Cancer | 220 | Exosome and miRNA | miRNeasyMinikit, RT-PCR, qRT-PCR and flow cytometry | The selected miR-1246, miR-4644, miR-3976 and miR-4306 were significantly upregulated in 83% of PDAC serum-exosomes, but rarely in control groups |
AUC: Area under the curve; CA19-9: Carbohydrate antigen 19-9; CTC: Circulating tumor cell; EphA2: Ephrin type-A receptor 2; EV: Extracellular vesicles; FACS: Fluorescence-activated cell sorting; ISET: Isolation by size of epithelial tumor cells; LC-MS: Liquid chromatography-tandemmass spectrometry; miRNA: microRNA; nPES: Nanoplasmon-enhanced scattering; NC: Normal healthy control; NE-iFISH: Negative enrichment immunofluorescence and in situ hybridization of chromosome 8; PDAC: Pancreatic ductal adenocarcinoma; RT-qPCR: Quantitative reverse transcription polymerase chain reaction; SE-iFISH: Subtraction enrichment and immunostaining-fluorescence in situ hybridization.